These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 33817709)
21. Medullary thyroid carcinoma in children: current state of the art and future perspectives. Kiriakopoulos A; Dimopoulou A; Nastos C; Dimopoulou D; Dimopoulou K; Menenakos E; Zavras N J Pediatr Endocrinol Metab; 2022 Jan; 35(1):1-10. PubMed ID: 34592078 [TBL] [Abstract][Full Text] [Related]
22. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671 [TBL] [Abstract][Full Text] [Related]
23. Management of medullary thyroid carcinoma. Jiménez C; Hu MI; Gagel RF Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338 [TBL] [Abstract][Full Text] [Related]
24. RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2). Castellone MD; Melillo RM Endocr Relat Cancer; 2018 Feb; 25(2):T105-T119. PubMed ID: 28931560 [TBL] [Abstract][Full Text] [Related]
25. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation. Frank-Raue K; Raue F Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387 [TBL] [Abstract][Full Text] [Related]
26. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Figlioli G; Landi S; Romei C; Elisei R; Gemignani F Mutat Res; 2013; 752(1):36-44. PubMed ID: 23059849 [TBL] [Abstract][Full Text] [Related]
27. Multiple endocrine neoplasia type 2. Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Tognarini I; Luzi E; Brandi ML Orphanet J Rare Dis; 2006 Nov; 1():45. PubMed ID: 17105651 [TBL] [Abstract][Full Text] [Related]
28. Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476 [No Abstract] [Full Text] [Related]
29. Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. Matrone A; Gambale C; Prete A; Elisei R Front Endocrinol (Lausanne); 2022; 13():864253. PubMed ID: 35422765 [TBL] [Abstract][Full Text] [Related]
30. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma]. Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438 [TBL] [Abstract][Full Text] [Related]
31. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127 [TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment. Boikos SA; Stratakis CA Histol Histopathol; 2008 Jan; 23(1):109-16. PubMed ID: 17952863 [TBL] [Abstract][Full Text] [Related]
33. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022 [TBL] [Abstract][Full Text] [Related]
34. Utilization of Genetic Testing for RET Mutations in Patients with Medullary Thyroid Carcinoma: a Single-Center Experience. Parkhurst E; Calonico E; Abboy S J Genet Couns; 2018 Dec; 27(6):1411-1416. PubMed ID: 29951718 [TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma. Silva AL; Carmo F; Moura MM; Domingues R; Espadinha C; Leite V; Cavaco B; Bugalho MJ Endocrine; 2015 Jun; 49(2):366-72. PubMed ID: 25725622 [TBL] [Abstract][Full Text] [Related]
36. [The treatment of medullary thyroid cancer]. Fujita T; Fujimori M Gan To Kagaku Ryoho; 2009 Oct; 36(10):1627-31. PubMed ID: 19838021 [TBL] [Abstract][Full Text] [Related]
37. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)". Fink M; Weinhüsel A; Niederle B; Haas OA Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874 [TBL] [Abstract][Full Text] [Related]
38. RET oncogene mutations in medullary thyroid carcinoma in Mexican families. González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374 [TBL] [Abstract][Full Text] [Related]
39. Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease. Jayakody S; Reagh J; Bullock M; Aniss A; Clifton-Bligh R; Learoyd D; Robinson B; Delbridge L; Sidhu S; Gill AJ; Sywak M World J Surg; 2018 May; 42(5):1432-1439. PubMed ID: 29484475 [TBL] [Abstract][Full Text] [Related]
40. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey. Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]